TY - JOUR AU - Rizvi, S. AU - Khan, S. A. AU - Hallemeier, C. L. AU - Kelley, R. K. AU - Gores, G. J. PY - 2018 DA - 2018// TI - Cholangiocarcinoma - evolving concepts and therapeutic strategies JO - Nat Rev Clin Oncol VL - 15 UR - https://doi.org/10.1038/nrclinonc.2017.157 DO - 10.1038/nrclinonc.2017.157 ID - Rizvi2018 ER - TY - JOUR AU - Rizvi, S. AU - Gores, G. J. PY - 2013 DA - 2013// TI - Pathogenesis, diagnosis, and management of cholangiocarcinoma JO - Gastroenterology VL - 145 UR - https://doi.org/10.1053/j.gastro.2013.10.013 DO - 10.1053/j.gastro.2013.10.013 ID - Rizvi2013 ER - TY - JOUR AU - Valle, J. PY - 2010 DA - 2010// TI - Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0908721 DO - 10.1056/NEJMoa0908721 ID - Valle2010 ER - TY - JOUR AU - Zappasodi, R. AU - Merghoub, T. AU - Wolchok, J. D. PY - 2018 DA - 2018// TI - Emerging concepts for immune checkpoint blockade-based combination therapies JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.03.005 DO - 10.1016/j.ccell.2018.03.005 ID - Zappasodi2018 ER - TY - JOUR AU - Ribas, A. AU - Wolchok, J. D. PY - 2018 DA - 2018// TI - Cancer immunotherapy using checkpoint blockade JO - Science VL - 359 UR - https://doi.org/10.1126/science.aar4060 DO - 10.1126/science.aar4060 ID - Ribas2018 ER - TY - JOUR AU - Chen, L. AU - Han, X. PY - 2015 DA - 2015// TI - Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80011 DO - 10.1172/JCI80011 ID - Chen2015 ER - TY - JOUR AU - Sullenger, B. A. AU - Nair, S. PY - 2016 DA - 2016// TI - From the RNA world to the clinic JO - Science VL - 352 UR - https://doi.org/10.1126/science.aad8709 DO - 10.1126/science.aad8709 ID - Sullenger2016 ER - TY - JOUR AU - Pardi, N. AU - Hogan, M. J. AU - Porter, F. W. AU - Weissman, D. PY - 2018 DA - 2018// TI - mRNA vaccines - a new era in vaccinology JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2017.243 DO - 10.1038/nrd.2017.243 ID - Pardi2018 ER - TY - JOUR AU - Pardi, N. AU - Hogan, M. J. AU - Weissman, D. PY - 2020 DA - 2020// TI - Recent advances in mRNA vaccine technology JO - Curr Opin Immunol VL - 65 UR - https://doi.org/10.1016/j.coi.2020.01.008 DO - 10.1016/j.coi.2020.01.008 ID - Pardi2020 ER - TY - JOUR AU - Gu, Y. Z. AU - Zhao, X. AU - Song, X. R. PY - 2020 DA - 2020// TI - Ex vivo pulsed dendritic cell vaccination against cancer JO - Acta Pharmacol Sin VL - 41 UR - https://doi.org/10.1038/s41401-020-0415-5 DO - 10.1038/s41401-020-0415-5 ID - Gu2020 ER - TY - JOUR AU - Shahnazari, M. AU - Samadi, P. AU - Pourjafar, M. AU - Jalali, A. PY - 2020 DA - 2020// TI - Therapeutic vaccines for colorectal cancer: the progress and future prospect JO - Int Immunopharmacol VL - 88 UR - https://doi.org/10.1016/j.intimp.2020.106944 DO - 10.1016/j.intimp.2020.106944 ID - Shahnazari2020 ER - TY - JOUR AU - Cafri, G. PY - 2020 DA - 2020// TI - mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer JO - J Clin Invest VL - 130 UR - https://doi.org/10.1172/JCI134915 DO - 10.1172/JCI134915 ID - Cafri2020 ER - TY - STD TI - Xu S, Yang K, Li R, Zhang L. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21186582. ID - ref13 ER - TY - JOUR AU - Hainsworth, J. D. PY - 2013 DA - 2013// TI - Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.3755 DO - 10.1200/JCO.2012.43.3755 ID - Hainsworth2013 ER - TY - JOUR AU - Razumilava, N. AU - Gores, G. PY - 2014 DA - 2014// TI - J Cholangiocarcinoma JO - Lancet VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61903-0 DO - 10.1016/S0140-6736(13)61903-0 ID - Razumilava2014 ER - TY - JOUR AU - Raggi, C. AU - Invernizzi, P. AU - Andersen, J. B. PY - 2015 DA - 2015// TI - Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts JO - J Hepatol VL - 62 UR - https://doi.org/10.1016/j.jhep.2014.09.007 DO - 10.1016/j.jhep.2014.09.007 ID - Raggi2015 ER - TY - JOUR AU - Farshidfar, F. PY - 2017 DA - 2017// TI - Integrative genomic analysis of Cholangiocarcinoma identifies distinct IDH-mutant molecular profiles JO - Cell Rep VL - 19 UR - https://doi.org/10.1016/j.celrep.2017.06.008 DO - 10.1016/j.celrep.2017.06.008 ID - Farshidfar2017 ER - TY - JOUR AU - Cerami, E. PY - 2012 DA - 2012// TI - The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0095 DO - 10.1158/2159-8290.CD-12-0095 ID - Cerami2012 ER - TY - JOUR AU - Tang, Z. AU - Kang, B. AU - Li, C. AU - Chen, T. AU - Zhang, Z. PY - 2019 DA - 2019// TI - GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis JO - Nucleic Acids Res VL - 47 UR - https://doi.org/10.1093/nar/gkz430 DO - 10.1093/nar/gkz430 ID - Tang2019 ER - TY - JOUR AU - Li, T. PY - 2020 DA - 2020// TI - TIMER2.0 for analysis of tumor-infiltrating immune cells JO - Nucleic Acids Res VL - 48 UR - https://doi.org/10.1093/nar/gkaa407 DO - 10.1093/nar/gkaa407 ID - Li2020 ER - TY - JOUR AU - Thorsson, V. PY - 2018 DA - 2018// TI - The Immune Landscape of Cancer JO - Immunity VL - 48 UR - https://doi.org/10.1016/j.immuni.2018.03.023 DO - 10.1016/j.immuni.2018.03.023 ID - Thorsson2018 ER - TY - JOUR AU - Yu, G. AU - Wang, L. G. PY - 2012 DA - 2012// TI - Han, Y. & he, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters JO - OMICS VL - 16 UR - https://doi.org/10.1089/omi.2011.0118 DO - 10.1089/omi.2011.0118 ID - Yu2012 ER - TY - STD TI - Sha D, et al. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020. https://doi.org/10.1158/2159-8290.CD-20-0522. ID - ref23 ER - TY - JOUR AU - Charoentong, P. PY - 2017 DA - 2017// TI - Pan-cancer Immunogenomic analyses reveal genotype-Immunophenotype relationships and predictors of response to checkpoint blockade JO - Cell Rep VL - 18 UR - https://doi.org/10.1016/j.celrep.2016.12.019 DO - 10.1016/j.celrep.2016.12.019 ID - Charoentong2017 ER - TY - JOUR AU - Sebastian, M. PY - 2014 DA - 2014// TI - Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-748 DO - 10.1186/1471-2407-14-748 ID - Sebastian2014 ER - TY - JOUR AU - Li, W. H. AU - Li, Y. M. PY - 2020 DA - 2020// TI - Chemical strategies to boost Cancer vaccines JO - Chem Rev VL - 120 UR - https://doi.org/10.1021/acs.chemrev.9b00833 DO - 10.1021/acs.chemrev.9b00833 ID - Li2020 ER - TY - JOUR AU - Luo, W. PY - 2020 DA - 2020// TI - Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory JO - Cancer Cell Int VL - 20 UR - https://doi.org/10.1186/s12935-020-1147-9 DO - 10.1186/s12935-020-1147-9 ID - Luo2020 ER - TY - JOUR AU - Hailemichael, Y. PY - 2018 DA - 2018// TI - Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy JO - J Clin Invest VL - 128 UR - https://doi.org/10.1172/JCI93303 DO - 10.1172/JCI93303 ID - Hailemichael2018 ER - TY - STD TI - Han S, et al. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12113404. ID - ref29 ER - TY - JOUR AU - Xu, J. L. AU - Guo, Y. PY - 2020 DA - 2020// TI - FCGR1A serves as a novel biomarker and correlates with immune infiltration in four Cancer types JO - Front Mol Biosci VL - 7 UR - https://doi.org/10.3389/fmolb.2020.581615 DO - 10.3389/fmolb.2020.581615 ID - Xu2020 ER - TY - JOUR AU - Guo, X. AU - Shen, W. PY - 2020 DA - 2020// TI - Latest evidence on immunotherapy for cholangiocarcinoma JO - Oncol Lett VL - 20 UR - https://doi.org/10.3892/ol.2020.12244 DO - 10.3892/ol.2020.12244 ID - Guo2020 ER - TY - JOUR AU - Thorsson, V. PY - 2019 DA - 2019// TI - The immune landscape of Cancer JO - Immunity VL - 51 UR - https://doi.org/10.1016/j.immuni.2019.08.004 DO - 10.1016/j.immuni.2019.08.004 ID - Thorsson2019 ER - TY - JOUR AU - Goeppert, B. PY - 2013 DA - 2013// TI - Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer JO - Br J Cancer VL - 109 UR - https://doi.org/10.1038/bjc.2013.610 DO - 10.1038/bjc.2013.610 ID - Goeppert2013 ER - TY - JOUR AU - Chapman, R. W. PY - 1999 DA - 1999// TI - Risk factors for biliary tract carcinogenesis JO - Ann Oncol VL - 10 UR - https://doi.org/10.1023/A:1008313809752 DO - 10.1023/A:1008313809752 ID - Chapman1999 ER - TY - JOUR AU - Randi, G. PY - 2009 DA - 2009// TI - Epidemiology of biliary tract cancers: an update JO - Ann Oncol VL - 20 UR - https://doi.org/10.1093/annonc/mdn533 DO - 10.1093/annonc/mdn533 ID - Randi2009 ER - TY - JOUR AU - Goydos, J. S. PY - 1998 DA - 1998// TI - Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker JO - Ann Surg VL - 227 UR - https://doi.org/10.1097/00000658-199803000-00012 DO - 10.1097/00000658-199803000-00012 ID - Goydos1998 ER - TY - STD TI - Job, S. et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma Hepatology, doi:https://doi.org/10.1002/hep.31092 (2019). ID - ref37 ER - TY - STD TI - Liu, Z. et al. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv, doi:https://doi.org/10.1101/2020.11.06.372037 (2020). ID - ref38 ER - TY - JOUR AU - Lu, S. PY - 2021 DA - 2021// TI - The immunodominant and neutralization linear epitopes for SARS-CoV-2 JO - Cell Rep VL - 34 UR - https://doi.org/10.1016/j.celrep.2020.108666 DO - 10.1016/j.celrep.2020.108666 ID - Lu2021 ER - TY - JOUR AU - Zhang, L. PY - 2020 DA - 2020// TI - SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-020-19808-4 DO - 10.1038/s41467-020-19808-4 ID - Zhang2020 ER - TY - STD TI - Khani E, Khiali S, Entezari-Maleki T. Potential COVID-19 therapeutic agents and vaccines: an evidence-based review. J Clin Pharmacol. 2021. https://doi.org/10.1002/jcph.1822. ID - ref41 ER - TY - STD TI - Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021. https://doi.org/10.1038/s41591-021-01230-y. ID - ref42 ER -